Archives

Responses Needed By July 29, 2022 Telling your story helps bring the Leber congenital amaurosis (LCA) community together. It also helps rare retinal disease advocates like us at Hope in […]

We’ve heard a lot about therapies to correct mutations in specific genes causing blindness or low vision, and now research is moving beyond single-gene correction to gene-independent therapies to [...]

Innovative funding initiatives created by the Foundation Fighting Blindness are accelerating research advances to find treatments for Leber congenital amaurosis (LCA) and other rare inherited [...]

Foundation Fighting Blindness begins its VISIONS 2022 national conference tomorrow, and Hope in Focus will be there to hear the latest research advances for Leber congenital amaurosis (LCA) and [...]

David Schulz has been appointed to our Board of Directors. He began his career at Pfizer Central Research as a Research Scientist in 1989 and was promoted to Executive Director […]

ProQR Therapeutics completed an in-depth strategic review to prioritize its objectives toward advancing RNA therapies, following news that its Illuminate Phase 2/3 clinical trial of sepofarsen in [...]

Working with preclinical data from multiple Leber congenital amaurosis (LCA) studies at the same time, Opus Genetics hopes to advance research into gene therapy for several forms of LCA at a [...]

Children living with visual impairment become more independent and empowered when parents set high expectations for their kids and challenge them every day. Just ask Beth Borysewicz. In her role [...]

After crazy months of looking for answers to questions about her infant’s vision, Melissa Matias learned her baby girl, Dylan, had a form of Leber congenital amaurosis known as LCA6 caused […]

ProQR Therapeutics’ clinical trials of sepofarsen to treat a form of Leber congenital amaurosis (LCA) caused by a mutation in the CEP290 gene did not meet its primary endpoint of […]